News

QNB Group Reports Impressive Financial Performance for 2024

QNB Group Reports Impressive Financial Performance for 2024

QNB Group's Strong Financial Year Performance

QNB Group, a leading financial institution in the MEA region, announces its outstanding financial results, approved by the Board of Directors. This marks a pivotal year for the group, culminating in remarkable performances across various sectors.

Dividend Distribution Announcement

The Board has recommended a generous cash dividend for shareholders amounting to 37% of the nominal share value, equating to QAR0.37 per share for the second half of the fiscal year. This comes from a total of 70% (QAR0.70 per share) calculated for the entire financial year. The proposed distribution reflects the record-breaking net profit accomplished by QNB Group.

Record Net Profit Growth

For the financial year that concluded in December, QNB Group reported a net profit surge of 8%, totaling QAR16.7 billion (USD4.6 billion). This increase highlights the overall financial health and operational effectiveness of the organization.

Total Assets and Client Growth

Total assets as of December reached QAR1,298 billion (USD357 billion), marking a 5% increase compared to the prior year. The growth is largely attributed to a 7% rise in loans and advances, accumulating to QAR911 billion (USD250 billion). Additionally, customer deposits saw a 3% increase, reaching QAR887 billion (USD244 billion), an achievement fostered by effective strategies for deposit growth.

Efficiency and Quality Management

QNB Group's efficiency is reflected in its cost-to-income ratio of 22.3%, emblematic of superior management practices in the MEA financial landscape. As of December, the group also maintained a low non-performing loan ratio of 2.8% and a full loan loss coverage ratio, which underscores the robust quality of its loan portfolio and adept credit risk management.

Equity and Capital Adequacy

The total equity of QNB Group ascended to QAR114 billion (USD31 billion), showing a 3% rise from the previous year. Earnings per share achieved QAR1.69 (USD0.46), further indicating positive growth outcomes throughout the year.

Regulatory Compliance Ratios

Capital adequacy ratio stood at a commendable 19.2%, with liquidity coverage and stable funding ratios at 179% and 101%, respectively. These ratios are satisfactory and exceed the requisite levels mandated by the regulatory authorities, showcasing QNB Group's commitment to financial stability.

Industry Presence and Workforce

QNB Group’s extensive reach includes operations in 28 countries across three continents, backed by around 900 branch locations and over 5,000 ATMs. The group employs more than 31,000 dedicated staff members who contribute to its enduring success.

Frequently Asked Questions

What were QNB Group's main financial highlights for 2024?

QNB Group reported a net profit of QAR16.7 billion, an 8% increase, with total assets reaching QAR1,298 billion, a 5% rise.

What is the recommended cash dividend for shareholders?

The Board recommended a cash dividend of 70% of the nominal share value for the year, translating to QAR0.70 per share.

How does QNB Group ensure financial stability?

QNB maintains a capital adequacy ratio of 19.2% and a low non-performing loans ratio of 2.8%, ensuring robust financial health.

Where does QNB Group operate?

QNB Group operates in 28 countries with approximately 900 locations globally, serving a diverse customer base.

What is QNB Group's employee strength?

QNB Group employs over 31,000 staff members across its extensive international network.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 316

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 0

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 291

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

Stretch Zone Expands Horizons with Canadian Studio Launch

Updated Category News Views 214

Stretch Zone's Exciting New Chapter in Canada Stretch Zone, a trailblazer in the realm of assisted stretching, has embarked on a significant milestone by opening its first studio in Canada. This new location is not just a store but a powerful symbol of the brand's commitment to enhance flexibility and mobility in communities beyond the United States. The Vision Behind the...

Continue Reading
Eilean Therapeutics Unveils Groundbreaking JAK2 Inhibitor ZE74-0282

Updated Category News Views 585

New Frontiers in JAK2 Inhibition by Eilean Therapeutics Eilean Therapeutics LLC, a pioneering biotechnology company, is set to make waves in cancer treatment with its latest development, ZE74-0282, a wild-type-sparing JAK2-JH2/V617F inhibitor. The company has announced an exciting presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, focusing...

Continue Reading
PodcastOne Extends LadyGang Contract as It Approaches 1000 Episodes

Updated Category News Views 116

PodcastOne Renews its Agreement with LadyGang Podcast PodcastOne, a key player in the podcasting world, is thrilled to announce the renewal of its contract with the immensely popular LadyGang podcast, hosted by Keltie Knight, Becca Tobin, and Jac Vanek. Launched in 2015 on PodcastOne, this engaging podcast has resonated with millions of listeners and is gearing up to...

Continue Reading
BCA Research Warns Upcoming Rate Cuts May Be Insufficient

Updated Category News Views 73

BCA Research Warns Rate Cuts May Arrive Too Late BCA Research has expressed concerns about the upcoming rate cuts, suggesting they might not effectively address a potential recession. The firm points out that the effects of monetary policy often lag, meaning the economy is still grappling with the repercussions of previous tightening measures. Market Sentiments and...

Continue Reading
SOMOS Pilates Nashville: A Vibrant Rebranding Journey

Updated Category News Views 235

SOMOS Pilates Nashville: A Vibrant Rebranding Journey In an inspiring shift, Studio Pilates Nashville has announced its rebranding as SOMOS Pilates Nashville. This transition marks a significant evolution, aimed at celebrating the studio's growth and commitment to community-centered movement practices. Welcoming a New Identity The rebranding initiative reveals more than...

Continue Reading